阿霉素异体脱钙骨基质骨粒骨水泥缓释体的制备及体外试验

目的：研制阿霉素异体脱钙骨基质骨粒骨水泥缓释体，并研究分析其体外药物缓释性能及对OS－9001骨肉瘤细胞的抑制能力，方法：按Urist等的方法制备异异体脱钙骨基质骨粒，通过冻干，真空吸附等处理，将阿霉素载入其中并与骨水泥按1：1比例复合，制得阿霉素异体钙骨基质骨粒骨水泥缓释体，对该缓释体进行体外药物释放及其浸出液的体外抑瘤试验。结果：该缓释体第1天释放量为总含量的19．23％，其第1，20，40及70天的浸出液对OS－9901骨肉瘤细胞的抑制率分别为64．27％，41．68％，28．71％，及24．32％，结论：该缓释体具有良好的缓释功能，在70d内对OS－9901骨肉瘤细胞维持良好的有效的抑制率。     

自制磷酸钙骨水泥缓释体中顺铂的体外缓释效能

目的:观察自制磷酸钙骨水泥缓释体对顺铂的体外药物缓释性能及其浸泡液对骨肉瘤细胞OS-9607的抑制能力。方法:实验于2004-09/2005-06在解放军第四军医大学唐都医院全军骨肿瘤研究所完成。①磷酸钙骨水泥的制备:将无水磷酸氢钙与碳酸钙按比例混合,1500℃高温煅烧6h形成磷酸四钙,和磷酸氢钙混合制成磷酸钙骨水泥固相成分;配置5%明胶溶液作为液相。②磷酸钙骨水泥缓释体的制备:按95mg磷酸钙骨水泥固相配5mg顺铂的配比,混合后加入液相制成直径10mm、厚3mm的圆片状样品,共5片,每片平均重1150mg,平均每片含顺铂50mg。同法制备不含顺铂的磷酸钙骨水泥样品3片作为阴性对照。③体外释放和体外抑制骨肉瘤细胞实验:随机抽取3片含顺铂样品及阴性对照,各置于0.1mol/L(pH7.4)的磷酸盐缓冲液中,37℃恒温振荡器保存,分别于第1,2,3,5,7,14,28,42,56天取浸泡液标本,用原子吸收分光光度计检测顺铂的释放浓度。四甲基偶氮唑蓝法检测经磷酸钙骨水泥缓释体浸泡液作用后的骨肉瘤细胞OS-9607的活力及代谢活性的变化。结果:①磷酸钙骨水泥缓释体的体外顺铂释放检测结果:浸泡前2d顺铂出现快速释放,分别占总量的21.62%和8.87%,以后在较低水平维持相对稳定的缓慢释放,释放时间持续56d以上。②磷酸钙骨水泥缓释体不同浸泡时间浸出液的顺铂含量及对骨肉瘤细胞OS-9607的抑制率:浸泡第1,14,28,56天的浸出液的顺铂含量分别为2.702,0.081,0.063,0.051g/L,对骨肉瘤细胞OS-9607的抑制率分别为67.78%,48.89%,35.56%和27.78%。结论:在模拟体内环境下,磷酸钙骨水泥对抗肿瘤药物顺铂有缓慢而持久的体外释放作用,且对骨肉瘤细胞OS-9607具有中等抑制效果。     

自制磷酸钙骨水泥缓释体中顺铂的体外缓释效能

目的：观察自制磷酸钙骨水泥缓释体对顺铂的体外药物缓释性能及其浸泡液对骨肉瘤细胞OS-9607的抑制能力。 方法：实验于2004-09／2005-06在解放军第四军医大学唐都医院全军骨肿瘤研究所完成。①磷酸钙骨水泥的制备：将无水磷酸氢钙与碳酸钙按比例混合，l500℃高温煅烧6h形成磷酸四钙，和磷酸氢钙混合制成磷酸钙骨水泥固相成分；配置5％明胶溶液作为液相。②磷酸钙骨水泥缓释体的制备：按95mg磷酸钙骨水泥固相配5mg顺铂的配比，混合后加入液相制成直径10mm、厚3mm的圆片状样品，共5片，每片平均重1150mg，平均每片含顺铂50mg。同法制备不含顺铂的磷酸钙骨水泥样品3片作为阴性对照。③体外释放和体外抑制骨肉瘤细胞实验：随机抽取3片含顺铂样品及阴性对照，各置于0．1mol／L（pH7．4）的磷酸盐缓冲液中，37℃恒温振荡器保存，分别于第1，2，3，5，7，14，28，42，56天取浸泡液标本，用原子吸收分光光度计检测顺铂的释放浓度。四甲基偶氮唑蓝法检测经磷酸钙骨水泥缓释体浸泡液作用后的骨肉瘤细胞OS-9607的活力及代谢活性的变化。 结果：①磷酸钙骨水泥缓释体的体外顺铂释放检测结果：浸泡前2d顺铂出现快速释放，分别占总量的21．62％和8．87％，以后在较低水平维持相对稳定的缓慢释放，释放时间持续56d以上。②磷酸钙骨水泥缓释体不同浸泡时间浸出液的顺铂含量及对骨肉瘤细胞OS-9607的抑制率：浸泡第1，14，28，56天的浸出液的顺铂含量分别为2．702。0．081，0．063，0．051g／L。对骨肉瘤细胞OS-9607的抑制率分别为67．78％。48．89％。35．56％和27．78％。 结论：在模拟体内环境下。磷酸钙骨水泥对抗肿瘤药物顺铂有缓慢而持久的体外释放作用。且对骨肉瘤细胞OS-9607具有中等抑制效果。     

异体骨基质明胶骨粒 /骨水泥复合材料结构特征及力学性能的初步分析

目的研究不同质量分数比的骨基质明胶骨粒 /骨水泥复合材料的结构特征及生物力学性能 . 方法按 Urist等的方法制备异体部分脱钙骨基质明胶骨粒 , 与骨水泥按不同比例混和制成含骨粒质量分数比分别为 0、 400、 500 mg/ g的复合材料 , 对其进行扫描电镜观察和抗压极限强度、抗弯极限强度测定 . 结果复合比例材料中骨粒与骨水泥均匀混合分布 , 无序排列 , 骨水泥相互延续构成材料的骨架 , 骨粒分布其间 ; 材料间存在较多 100～ 400 μ m的不规则的自然裂隙 , 随材料中骨粒所占比例增加 , 骨水泥含量减少 , 自然裂隙增多 . 结论部分脱钙骨基质明胶骨粒 /骨水泥复合材料具有良好的生物力学性能 , 其中的 100～ 400 μ m自然裂隙有利于宿主骨的长入 , 是很好的骨移植替代材料 .     

异体脱钙骨基质颗粒复合骨水泥修复兔下颌骨缺损的放射影像学和组织学研究

目的探讨异体脱钙骨基质颗粒和骨水泥复合修复下颌骨骨缺损的效果。方法用异体脱钙骨基质颗粒复合骨水泥修复兔右下颌骨的骨缺损,左侧单纯植入骨水泥做对照。分别于术后不同时间行X-射线照相、99mTc-MDP骨扫描、组织学观察。结果4周开始形成骨痂,12周骨痂最丰富,24周复合材料与宿主骨边缘模糊,边缘部分的异体脱钙骨基质颗粒被新生骨替代,并与宿主骨融合。结论异体脱钙骨基质颗粒和骨水泥复合易塑形,还具有生物学活性,是修复下颌骨缺损的理想材料。     

同种异体脱钙骨基质的组织工程学特性

背景:由骨衍生的支架材料无论形态学和力学特征,具有合成材料无可比拟的优势,脱钙骨基质具有和自体骨最接近的三维结构,同时以Ⅰ型胶原为主,胶原是细胞黏附和生长的良好支架.目的:从组织工程学角度研究同种异体脱钙骨基质的生物学特性,探讨其作为软骨组织工程支架材料的可行性.方法:据Urist描述的方法制备青紫蓝兔同种异体脱钙骨基质,扫描电镜观察脱钙骨基质的超微结构,测定其孔径、孔隙率和降解率,测定同种异体脱钙骨基质与骨髓间充质干细胞的黏附率,兔体内植入法评价同种异体脱钙骨基质的组织相容性.结果与结论:脱钙骨基质呈多孔海绵状三维结构,孔径在210-320 um之间,孔隙率为92%,体外降解12周降解率达90%以上,脱钙骨基质与骨髓间充质干细胞共培养第2,4,6天的黏附率分别为(51.50±2.30)%,(94.13±2.14)%和(87.24±1.75)%.兔体内植入6周后脱钙骨基质周围界面未引起明显的炎症和排斥反应,并形成软骨样结构和少量骨组织.说明脱钙骨基质具有适宜的三维多孔结构,降解时间和软骨形成时间同步,同种异体脱钙骨基质与种子细胞黏附率高,与细胞组织相容性好,能满足软骨组织工程对支架材料的要求,是理想的软骨组织工程的支架材料.     

异体脱钙骨基质颗粒复合骨水泥修复兔股骨粉碎性骨折

目的探讨异体脱钙骨基质颗粒复合骨水泥修复严重粉碎性骨折的效果。方法制造兔右股骨粉碎性骨折的动物模型,a组用异体脱钙骨基质颗粒复合骨水泥并表面贴附自体骨渣进行修复;b组用异体脱钙骨基质颗粒复合骨水泥进行修复;c组单纯植入骨水泥进行修复作为对照组。分别于术后不同时间行X射线照相、99mTc-MDP骨扫描和组织学观察。结果a组和b组4周开始形成骨痂,12周骨痂最丰富,24周复合材料与宿主骨边缘模糊,边缘部分的异体脱钙骨基质颗粒被新生骨替代,并与宿主骨融合。a组较b组骨痂形成快。99mTc-MDP骨扫描计数a组大于b组,b组大于c组(P<0.01)。结论异体脱钙骨基质颗粒复合骨水泥易塑形,并具有生物学活性,能修复粉碎性骨折,表面贴附自体骨渣进行修复效果更为理想。     

异体脱钙骨基质颗粒复合骨水泥修复兔股骨粉碎性骨折

目的：探讨异体脱钙骨基质颗粒复合骨水泥修复严重粉碎性骨折的效果。方法：制造兔石股骨粉碎性骨折的动物模型，a组用异体脱钙骨基质颗粒复合骨折泥并表面贴附自体骨渣进行修复；b组用异体脱钙骨基质颗粒复合骨水泥进行修复；c组单纯植入骨水泥进行修复作为对照组。分别于术后不同时间行X射线照相、^99mTc-MDP骨扫描和组织学观察。结果：a组和b组4周开始形成骨痂，12周骨痂最丰富，24周复合材料与宿主骨边缘模糊，边缘部分的异体脱钙骨基质颗粒被新生骨替代，并与宿主骨融合。a组较b组骨痂形成快。^99mTc-MDP骨扫描计数a组大于b组，b组大于c组（P＜0．01）。结论：异体脱钙骨基质颗粒复合骨水泥易塑形，并具有生物学活性，能修复粉碎性骨折，表面贴附自体骨渣进行修复效果更为理想。     

异体脱钙骨基质-利福平明胶复合材料治疗修复兔桡骨缺损的实验研究

目的 研究异体脱钙骨基质(DBM)-利福平明胶复合体作为抗结核植骨复合材料,对兔桡骨缺损修复的能力及其缓释效果.方法 参考Urist操作方法制备兔同种异体DBM并与载有利福平的明胶复合体制备抗结核复合材料,通过标准兔桡骨缺损模型观察复合材料骨修复特性及利福平缓释效果.结果 异体DBM-利福平明胶复合材料能够有效修复骨缺损并达到药物缓释的目的 .结论 异体DBM-利福平明胶复合材料具有良好的成骨活性和药物缓释效果,可作为临床植骨的缓释药物使用,其临床应用效果可望进一步研究.     

骨缺损修复材料可降解速固化骨水泥结构特征及力学性能

目的分析异体脱钙骨基质(DBM)骨粒复合磷酸钙骨水泥(CPC)及氰基丙烯酸正丁酯粘合剂(NBCA)后材料的扫描电镜结构特征及生物力学性能。方法将DBM骨粒与CPC以1:1体积比搅拌均匀,加入适量NBCA,制成DCN骨水泥;扫描电镜观察复合材料结构特征,力学试验机测定材料生物力学性能。结果扫描电镜发现,CPC与DBM均匀复合,CPC被覆DBM表面呈规则有序海绵状,其中存在较多大小不规则、相互连通的自然裂隙;材料的抗压及拉伸极限强度较CPC明显提高。结论DCN骨水泥具有相互联通的自然裂隙及潜在的骨粒通道,并可提供较好的机械支持和固定作用的骨修复材料。     

异体脱钙骨基质骨粒复合骨水泥骨缺损修复材料结构特征及生物力学性能

INTRODUCTIONAsthematerialstorepairthebonedefect，bonecementandde－calcifiedbonematrixareusuallyusedinclinic．Forresearchingthematerialwhichhasthecapabilityofboneinductionandbiome－chanicalstrength，wedesignedthecompoundbiomedicalmaterialimpregnatedthedecalcifiedbonematrixwithbonecementandanalyzedit＇sconstructiveandbiomechanicalproperties．MATERIALSANDMETHODSPreparationofDBMparticlesAccordingtotheUrist＇smethods[１]，thecortexboneseliminatedthesofttissueandmarrowwerebrokenintopie…     

Chitosan-poly(butylene succinate) scaffolds and human bone marrow stromal cells induce bone repair in a mouse calvaria model

Tissue engineering sustains the need of a three-dimensional (3D) scaffold to promote the regeneration of tissues in volume. Usually, scaffolds are seeded with an adequate cell population, allowing their growth and maturation upon implantation in vivo. Previous studies obtained by our group evidenced significant growth patterns and osteogenic differentiation of human bone marrow mesenchymal stem cells (hBMSCs) when seeded and cultured on melt-based porous chitosan fibre mesh scaffolds (cell constructs). Therefore, it is crucial to test the in vivo performance of these in vitro 3D cell constructs. In this study, chitosan-based scaffolds were seeded and cultured in vitro with hBMSCs for 3 weeks under osteogenic stimulation conditions and analysed for cell adhesion, proliferation and differentiation. Implantation of 2 weeks precultured cell constructs in osteogenic culture conditions was performed into critical cranial size defects in nude mice. The objective of this study was to verify the scaffold integration and new bone formation. At 8 weeks of implantation, scaffolds were harvested and prepared for micro-computed tomography (μCT) analysis. Retrieved implants showed good integration with the surrounding tissue and significant bone formation, more evident for the scaffolds cultured and implanted with human cells. The results of this work demonstrated that chitosan-based scaffolds, besides supporting in vitro proliferation and osteogenic differentiation of hBMSCs, induced bone formation in vivo. Thus, their osteogenic potential in orthotopic location in immunodeficient mice was validated, evidencing good prospects for their use in bone tissue-engineering therapies.     

牛煅烧骨颗粒复合骨水泥的生物力学性能评定

目的分析不同质量比的牛煅烧骨颗粒复合骨水泥结构特征及生物力学性能.方法把提取过bBMP的牛骨颗粒制成煅烧骨,以不同的质量比与骨水泥混合制成复合材料,测定其生物力学性能与电镜下结构.结果复合材料呈均匀混合分布并多点状结合,其中存在较多的裂隙;含牛煅烧骨颗粒质量比为500mg/g的复合材料的生物力学性能最为适宜.结论牛煅烧骨颗粒复合骨水泥后具有新骨长入的通道,含煅烧骨质量比为500mg/g的复合材料生物力学性能良好,能作为支架材料修复骨缺损.     

骨形态发生蛋白2/聚乳酸缓释微球的制备及表征

背景：聚乳酸具有良好的生物相容性,是优良的药物缓释载体。 目的：制备重组人骨形态发生蛋白2/聚乳酸缓释微球,考察其理化特性。 方法：采用复乳溶剂挥发法制备重组人骨形态发生蛋白2/聚乳酸缓释微球,进行扫描电镜、激光粒度、Zeta电位、溶胀性能检测及采用ELISA试剂盒检测包封率、载药率及体外释药率。 结果与结论：扫描电镜见重组人骨形态发生蛋白2/聚乳酸缓释微球微球近似圆形,形态较规则,分散性较好,表面光滑。激光粒度分析重组人骨形态发生蛋白2/聚乳酸缓释微球微平均粒径839.6 nm,Zeta电位（-32.93±3.74）mV,微球溶胀系数1.157±0.059,包封率及载药率分别为（88.943±2.878）%,（0.026±0.001）%;微球在第1天释药约10.199%,随后释药较恒定,至第19天累计释药率为54.643%。说明制备出的重组人骨形态发生蛋白2/聚乳酸缓释微球的粒径达到中华人民共和国药典第10版二部关于亚微球的定义标准及包封率不低于80%的要求,并且在体外具有很好的缓释功能。     

组织工程化骨替代材料的评价及其在修复骨肿瘤性骨缺损中的应用

目的制备和综合评价组织工程化骨替代材料并用于修复骨肿瘤所导致的骨缺损。方法制备狗和人的异体脱钙骨基质颗粒(DBM),提取牛骨形成蛋白(bBMP)并经成骨诱导活性测定,将bBMP与DBM用直接掺和的方法复合后,再与骨水泥(BC)混合制成组织工程化复合材料,进行综合评价后备用。56例下肢骨肿瘤患者在微波诱导高温原位灭活后,应用组织工程化复合材料对遗留的骨缺损进行修复重建。结果bBMP、DBM和BC组织工程化复合骨修复替代材料具有良好的生物相容性、很强的生物力学强度和成骨诱导活性,并且具有良好的粘合性和可塑形性。临床应用56例,经平均9个月的随访,效果良好且无任何不良反应。患肢膝关节功能评价,优52例(93%),良4例(7%),优良率100%。结论bBMP、DBM和BC组织工程化复合骨修复替代材料是目前修复骨缺损理想的产品,有广阔的临床应用前景。     

Nanostructured gellan and xanthan hydrogel depot integrated within a baghdadite scaffold augments bone regeneration

Controlled delivery of biological cues through synthetic scaffolds to enhance the healing capacity of bone defects is yet to be realized clinically. The purpose of this study was development of a bioactive tissue‐engineered scaffold providing the sustained delivery of an osteoinductive drug, dexamethasone disodium phosphate (DXP), encapsulated within chitosan nanoparticles (CN). Porous baghdadite (BD; Ca₃ZrSi₂O₉) scaffolds, a zirconia‐modified calcium silicate ceramic, was coated with DXP‐encapsulated CN nanoparticles (DXP–CN) using nanostructured gellan and xanthan hydrogel (GX). Crosslinker and GX polymer concentrations were optimized to achieve a homogeneous distribution of hydrogel coating within BD scaffolds. Dynamic laser scattering indicated an average size of 521 ± 21 nm for the DXP–CN nanoparticles. In vitro drug‐release studies demonstrated that the developed DXP–CN–GX hydrogel‐coated BD scaffolds (DXP–CN–GX–BD) resulted in a sustained delivery of DXP over the 5 days (78 ± 6% of drug release) compared with burst release over 1 h, seen from free DXP loaded in uncoated BD scaffolds (92 ± 8% release in 1 h). To estimate the influence of controlled delivery of DXP from the developed scaffolds, the effect on MG 63 cells was evaluated using various bone differentiation assays. Cell culture within DXP–CN–GX–BD scaffolds demonstrated a significant increase in the expression of early and late osteogenic markers of alkaline phosphatase activity, collagen type 1 and osteocalcin, compared to the uncoated BD scaffold. The results suggest that the DXP‐releasing nanostructured hydrogel integrated within the BD scaffold caused sustained release of DXP, improving the potential for osteogenic differentiation. Copyright © 2015 John Wiley & Sons, Ltd.     

Studies on alginate-chitosan microcapsules and renal arterial embolization in rabbits.

Spherical and well-dispersed alginate-chitosan microcapsules, with a mean diameter of 77.28+/-0.93 microm (n=3), were prepared by the emulsification-gelation method. Adriamycin hydrochloride (ADM) was used as a model drug to investigate the drug loading capacity and release characteristics of the microcapsules. The drug/carrier ratio and chitosan concentration influenced the encapsulation efficiency of adriamycin. The adriamycin release from microcapsules was obviously different in 0.1 mol/l HCl from that in phosphate-buffered saline (PBS, pH 7.4). The drug was completely and rapidly released in 0.1 mol/l HCl, while it showed a sustained release after a burst release in PBS. The increase in chitosan concentration had no effect on adriamycin release in PBS. Using sulforhodamin B (SRB)-staining survival assay, the inhibition of adriamycin alginate-chitosan microcapsules (ADM-ACM) to different cancer cell lines (human BGC-823 cells, Bel-7402 cells and Hela cells) in vitro was determined. The inhibitory rate of ADM-ACM suspension to the three cell lines significantly outran that of ADM solution, no matter at high or low concentration. The effects of blank alginate-chitosan microcapsules (BACM) on renal arterial embolization were examined with transcatheter arterial embolization in rabbits. The angiogram and histopathological results indicated the blank microcapsules had excellent short- and long-term effects on renal arterial embolization.     

Osteogenic potential of adipogenic predifferentiated human bone marrow‐derived multipotent stromal cells for bone tissue‐engineering

In the present study, we evaluated the benefits of an adipogenic predifferentiation, the pathway most closely related to osteoblastogenesis, on the pro‐osteogenic potential of human adult multipotent bone marrow stromal cells (hBMSCs), both in vitro and in vivo. Adipogenic differentiation of hBMSCs for 14 days resulted in a heterogeneous cell population from which the most adipogenic‐committed cells were eliminated by their lack of readhesion ability. Our results provided evidence that the select adherent adipogenic differentiated hBMSCs (sAD+ cells) express a gene profile characteristic of both adipogenic and osteogenic lineages. In vitro, when cultured in osteogenic medium, sAD+ differentiated along the osteogenic lineage faster than undifferentiated hBMSCs. In vivo, in an ectopic mouse model, sAD+ exhibited a significantly higher bone formation capability compared with undifferentiated hBMSCs. We sought, then, to investigate the underlying mechanisms responsible for such beneficial effects of adipogenic predifferentiation on bone formation and found that this outcome was not linked to a better cell survival post‐implantation. The secretome of sAD+ was both proangiogenic and chemoattractant, but its potential did not supersede the one of undifferentiated hBMSCs. However, using co‐culture systems, we observed that the sAD+ paracrine factors were pro‐osteogenic on undifferentiated hBMSCs. In conclusion, adipogenic priming endows hBMSCs with high osteogenic potential as well as pro‐osteogenic paracrine‐mediated activity. This preconditioning appears as a promising strategy for bone tissue engineering technology in order to improve the hBMSC osteogenic potency in vivo.     

Fabrication of a biomimetic ZeinPDA nanofibrous scaffold impregnated with BMP‐2 peptide conjugated TiO2 nanoparticle for bone tissue engineering

A biomimetic Zein polydopamine based nanofiber scaffold was fabricated to deliver bone morphogenic protein‐2 (BMP‐2) peptide conjugated titanium dioxide nanoparticles in a sustained manner for investigating its osteogenic differentiation potential. To prolong its retention time at the target site, BMP‐2 peptide has been conjugated to titanium dioxide nanoparticles owing to its high surface to volume ratio. The effect of biochemical cues from BMP‐2 peptide and nanotopographical stimulation of electrospun Zein polydopamine nanofiber were examined for its enhanced osteogenic expression of human fetal osteoblast cells. The sustained delivery of bioactive signals, improved cell adhesion, mineralization, and differentiation could be attributed to its highly interconnected nanofibrous matrix with unique material composition. Further, the expression of osteogenic markers revealed that the fabricated nanofibrous scaffold possess better cell—biomaterial interactions. These promising results demonstrate the potential of the composite nanofibrous scaffold as an effective biomaterial substrate for bone regeneration.     

缓释型重组人骨形态发生蛋白2/壳聚糖生物骨修复材料诱导骨形成

背景:重组人骨形态发生蛋白2在体内半衰期短、易降解代谢,达不到理想的骨再生效果。目的:制备缓释型重组人骨形态发生蛋白2/壳聚糖生物骨修复材料,并观察其缓释性能、骨诱导活性。方法:将重组人骨形态发生蛋白2与壳聚糖混合制备壳聚糖膜,涂覆于生物骨修复材料表面,ELISA方法检测其体外释药性能。茜素红染色检测缓释型人骨形态发生蛋白2/壳聚糖生物骨材料、重组人骨形态发生蛋白2生物骨材料、单纯骨填充材料诱导C2C12细胞骨钙蛋白的形成,观察其诱导成骨细胞能力。同时将3种骨修复材料植入清洁级KM小鼠股部肌袋内,2周后检测新生骨Ca2+离子含量,评价其异位骨诱导能力。结果与结论:材料表面的壳聚糖膜分布均匀,负载的重组人骨形态发生蛋白2呈团簇状。重组人骨形态发生蛋白2/壳聚糖生物骨修复材料体外释药存在突释,前4d释放量达总药量的50%,持续至12d,释药量达到90%,第18天时释放完全。与单纯骨填充材料、重组人骨形态发生蛋白2生物骨材料相比,缓释型人骨形态发生蛋白2/壳聚糖生物骨修复材料诱导C2C12细胞向成骨晚期分化能力与异位骨形成能力显著增强(P<0.05)。结果提示缓释型人骨形态发生蛋白2/壳聚糖生物骨修复材料缓释性能好,促进骨形成能力强。